Ardelyx, Inc.
(NASDAQ : ARDX)

( )
ARDX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.27%93.671.3%$1008.13m
BIIBBiogen Inc.
0.54%231.461.3%$690.83m
AMGNAmgen Inc.
0.41%180.491.3%$471.95m
GILDGilead Sciences, Inc.
0.10%63.100.9%$441.95m
ILMNIllumina, Inc.
0.26%322.883.5%$285.89m
REGNRegeneron Pharmaceuticals, Inc.
0.83%347.002.6%$277.64m
VRTXVertex Pharmaceuticals Incorporated
4.07%175.371.9%$247.10m
ALXNAlexion Pharmaceuticals, Inc.
-0.28%132.002.0%$174.70m
EXASExact Sciences Corporation
3.61%93.9425.3%$160.74m
SRPTSarepta Therapeutics, Inc.
0.00%118.0914.7%$144.55m
AAgilent Technologies, Inc.
-0.04%75.541.6%$142.04m
ONCESpark Therapeutics, Inc.
0.00%110.6011.2%$133.55m
INCYIncyte Corporation
2.38%75.412.5%$98.69m
IONSIonis Pharmaceuticals, Inc.
0.00%75.008.3%$95.31m
BMRNBioMarin Pharmaceutical Inc.
0.00%86.004.3%$93.68m

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.